empty
 
 
nl
Search
Ondersteuning
Direct openen van een account
Trading Platform
Storting/opname
Search
Voor beginners Voor traders Voor partners Neem een ​​pauze About InstaSpot
nl
#BMY Terug naar de lijst met instrumenten #CGC

Valuta converter

BioNTech SE
93.98 USD
10 Dec 2025 18:51
Prijsverandering (% chg)
$0
(0%)
Vorige close
Vorige close

Sluitprijs, de vorige dag.
$95.19
Open
Open

Openingsprijs.
$96.61
Hoog dag
Hoog dag

Hoogste prijs over vorige trading dag.
$95.12
Laag dag
Laag dag

De laagste prijs voor de laatste handelsdag
$93.8
52-wk Hoog
52-wk Hoog

Prijsklasse hoog in de laatste 52 weken
$96.64
52-wk Laag
52-wk Laag

Prijsklasse laag in de laatste 52 weken
$93.8
Download archief
Buy
93.98
Sell
93.98
Open the chart in full screen view
Buy
93.98
Sell
93.98
Download archief
Open the chart in full screen view

BioNTech SE. About company

BioNTech SE. is a biotechnology company founded in 2008 in Germany. It develops medicines for the treatment of cancer, HIV, tuberculosis, and other diseases.

In 2020, BioNTech SE. participated in the creation of a COVID-19 vaccine together with Pfizer and Fosun Pharma. As of March 2022, BioNTech SE. and Pfizer have delivered more than 3.1 billion doses of vaccines.

The company owns a factory in Marburg but most of the vaccines are produced at Pfizer and other companies' factories. In 2021, BioNTech SE. announced its plan to open its first vaccine manufacturing facility in Rwanda.

Its market cap currently stands at $33.38 billion. In 2021, its revenue amounted to $18,976 billion. The net profit totaled $10,292 billion.

BioNTech SE. shares and what factors impact them

BioNTech SE. stock has been traded on the NASDAQ exchange under the BNTX ticker since 2019. The initial price was $15.

Nowadays, the stock price is estimated at $135-$138. Over the year, it fluctuated in the range of $117 - $370.

In 2022, the company paid dividends to the shareholders in the amount of $2.11 per share. The yield was 1.65%.

You should pay attention to the following factors when trading its stock:

  • News about rivals that produce medicines and vaccines;
  • Likelihood of a high profit from the development of an Omicron vaccine;
  • Dependence on government agencies that regulate the industry and the production of coronavirus vaccines.

Kan u nu niet praten?
Stel uw vraag in de chat.